Philips Capital Markets Day 2026 Summary Company Overview - **Company**: Koninklijke Philips (NYSE:PHG) - **Industry**: Health Technology - **Focus**: Innovation in health technology, particularly in diagnosis, treatment, connected care, and personal health Key Points and Arguments Company Strategy and Vision - Philips aims to drive profitable growth and deliver sustainable value through innovation and improved operational performance [3][4][5] - The company has improved its culture, team, and business fundamentals over the past three years, positioning itself for growth acceleration [4][5][10] - Philips has a clear ambition to improve the lives of 2.5 billion people by 2030, building on the 2 billion lives improved by 2025 [8] Market Position and Leadership - Philips holds leading positions in various segments: - Number one in catheterization lab systems, interventional cardiology, cardiac ultrasound, grooming, and medical device integration [3] - Top three in diagnostic imaging and number two in oral health care and sleep and respiratory care [3] - The company has a global footprint with over 2.5 million systems installed, reaching 80% of top hospitals worldwide [19] Financial Performance and Targets - Philips aims for mid-single-digit compound annual growth rate (CAGR) and mid-teens margins by 2028, with strong cash generation of EUR 4.5 billion to EUR 5 billion over the planned period [19][41] - The company has expanded its margins by nearly 500 basis points to over 12% and targets mid-teens margins in the next three years [45] - Cash flow targets include EUR 1.3 billion to EUR 1.5 billion in 2026 and EUR 4.5 billion to EUR 5 billion cumulatively over the planned period [46] Innovation and Product Development - Philips has shifted to a business-led innovation model, focusing on customer needs and accelerating the speed of innovation [12][34] - The company has launched several groundbreaking products, including the world's first helium-free 3T MRI and advancements in ultrasound technology [25][34] - AI and data integration are central to Philips' innovation strategy, enhancing clinical decision-making and operational efficiency [17][36] Operational Improvements - Philips has simplified its operations, reducing overlapping quality management systems by over 75% and improving customer fill rates by more than 20% [14][15] - The company has implemented a decentralized decision-making model, enhancing agility and responsiveness to market demands [15] - A productivity program aims to deliver an additional EUR 1.5 billion in savings over the next three years, focusing on cost competitiveness and lean operations [59][60] Market Dynamics and Growth Opportunities - The healthcare market is projected to grow at 3%-5% annually, driven by an aging population and increasing chronic disease prevalence [16][17] - There is a widening gap between the demand for healthcare services and supply, presenting significant innovation opportunities for Philips [16] - North America is identified as a key growth engine, with double-digit growth observed in 2025 [32] Challenges and Risks - Philips acknowledges the uncertain macro environment, including potential impacts from tariffs and ongoing litigation related to the Respironics recall [46][42] - The company is committed to navigating these challenges while maintaining focus on its strategic goals [42] Conclusion - Philips is positioned for a strong future with a clear strategy focused on innovation, operational excellence, and market leadership in health technology [43][44] - The company emphasizes its commitment to delivering better care for more people while driving profitable growth and creating sustainable value [42][43]

Core Insights - Philips reported strong fourth-quarter results with a 7% growth in order intake and comparable sales, reflecting consistent delivery against commitments and improving order momentum [5][6] - The company achieved EUR 248 million in productivity savings in Q4, bringing total productivity savings to EUR 850 million for 2025, exceeding the original outlook [1][6] - For 2026, Philips anticipates comparable sales growth of 3% to 4.5% and an adjusted EBITDA margin of 12.5% to 13% [17] Financial Performance - In Q4, Philips generated EUR 1.2 billion in free cash flow, although this was EUR 85 million lower year over year due to a prior year's insurance receipt [8] - The company ended the quarter with approximately EUR 2.8 billion in cash and net debt of approximately EUR 5.3 billion, with a leverage ratio of 1.7x net debt to adjusted EBITDA [9] - Full-year free cash flow was EUR 512 million, ahead of outlook, following significant cash payments related to U.S. medical monitoring settlements [8] Sales and Order Intake - Order intake grew 6% for the full year, with equipment order intake rising 7% in Q4, driven by strong performance in North America [2][5] - For 2025, comparable sales growth was reported at 2.3%, with an adjusted EBITDA margin increase of 80 basis points to 12.3% [3] Segment Performance - Connected Care saw a 7% growth in comparable sales in Q4, supported by strong demand in monitoring and enterprise informatics [3] - The D&T segment reported a 5% increase in order intake for the year, with strong demand for Image-Guided Therapy and Precision Diagnosis [11] Strategic Initiatives - Philips announced an additional EUR 1.5 billion productivity program for 2026-2028, aimed at further enhancing operational efficiency [19] - The company emphasized innovation as a key driver of growth, highlighting new product launches such as a helium-free MRI and an AI-enabled navigation solution [10] Regional Insights - North America showed strong market fundamentals with increasing demand for secure, productivity-enhancing platforms, while China presented challenges due to longer processing times and tougher competition [14][15] - In Personal Health, demand remained resilient in the U.S., but consumer sentiment in China was cautious, leading to a reduction in trade inventory [16] Tariff Impact - Incremental tariff headwinds were slightly better than expected, with mitigation actions in place to fully address these challenges by 2028 [7] - For 2026, tariff costs are expected to have a net impact of EUR 250 million to EUR 300 million, with a slight decline in margin anticipated in Q1 due to these headwinds [18]

Core Viewpoint - Royal Philips has announced the expanded commercial availability of LumiGuide 3D Device Guidance, the first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States, marking a significant advancement in radiation-free navigation technology [2][10]. Group 1: Product Overview - LumiGuide allows physicians to visualize and guide devices inside the body using light instead of continuous X-ray, enhancing radiation safety and dose reduction in image-guided therapy [2][5]. - The technology integrates seamlessly with Philips' Azurion platform, which is designed to drive procedural innovation across various clinical domains [3][9]. - LumiGuide utilizes Fiber Optic RealShape (FORS) technology to provide high-resolution, full-color images in real-time, enabling precise navigation during complex endovascular procedures [5][8]. Group 2: Clinical Impact - Clinical experiences indicate that LumiGuide can improve efficiency, reduce procedure time, and minimize fluoroscopy pedal usage, with complex aortic repair procedures performed 37% faster and with up to 56% reduction in dose area product (DAP) [4][5]. - Over 2,000 clinical procedures have utilized LumiGuide, demonstrating its effectiveness and integration with the Azurion platform [10]. Group 3: Market Expansion - Following a successful limited market release in late 2023, LumiGuide will be commercially available from January 2026 in key European markets and the United States, expanding access to advanced image-guided therapy [10][14]. - Philips aims to enhance the adoption of this technology in hospitals to improve treatment precision and safety while reducing radiation risks for both patients and clinical staff [6][7]. Group 4: Commitment to Safety - LumiGuide is part of Philips' broader portfolio aimed at reducing or eliminating radiation exposure during image-guided procedures, reinforcing the company's leadership in low- and no-dose interventional solutions [11][14]. - The integration of LumiGuide with other technologies like Azurion with ClarityIQ and DoseAware further emphasizes Philips' commitment to advancing radiation safety in medical procedures [11].